Tag: GlobeNewswire

ANNOUNCEMENT NO. 316
2 October 2026

ChemoMetec A/S has completed the share buyback programme announced in company announcement no. 309 dated 15 May 2026. The programme provided for the repurchase of up to 500,000 shares for a total consideration of up to DKK 100 million.

Under the programme, ChemoMetec A/S repurchased a total of 239,950 shares for a total consideration of DKK 99,998,735.

Following completion of the programme, ChemoMetec A/S holds a total of 239,950 treasury shares, corresponding to 1.38% of the company’s share capital.

Additional Information

Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80 

Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80 

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

TORONTO, Oct. 02, 2026 (GLOBE NEWSWIRE) — BULGOLD Inc. (TSXV:ZLTO) (the “Company” or “BULGOLD“) is pleased to announce that it has engaged HE Capital Markets Ltd (“HECM“) to provide investor engagement services across North America and Europe.

In connection with this engagement, the Company and HECM have entered into an agreement (the “Agreement“), pursuant to which HECM will provide investor engagement services in accordance with Policy 3.4 – Investor Relations, Promotional and Market-Making Activities of the TSX Venture Exchange (the “TSXV“), including providing company updates, announcements, interviews, articles and other relevant communications across HECM’s investor network and through media and digital channels. HECM will also prepare articles, fact sheets and supporting materials covering the Company’s assets, strategy, key milestones and overall investment proposition.

Subject to the approval of the TSXV, the Agreement will be effective October 6, 2026, with a 3-month initial term (subject to any mutually agreed extension). Either party may cancel the agreement upon 30-days’ prior written notice. The Company will pay HECM the aggregate amount of US$9,000 for 3 months of services.

HECM is a full-service investor relations firm that works with North American companies to optimize visibility in North America and Europe. HECM’s head office is located at 3 London Bridge Street, London, SE1 9SG, United Kingdom. As of the date hereof, to the Company’s knowledge, HECM (including its directors and officers) does not own any securities of the Company and has an arm’s length relationship with the Company. The Company will not issue any securities to HECM as compensation for its services and there are no performance factors contained in the Agreement.

About BULGOLD Inc.

BULGOLD is a gold exploration company focused on the exploration and development of mineral exploration projects in Central and Eastern Europe. The Company controls 100% of three quality quartz-adularia epithermal gold projects located in the Bulgarian and Slovak portions of the Western Tethyan Belt: the Lutila Gold Project, the Kostilkovo Gold Project and the Kutel Gold Project. Management of the Company believes that its assets show potential for high-grade, good-metallurgy, low-sulfidation epithermal gold mineralisation.

On June 30, 2026, BULGOLD’s issued and outstanding shares were 72,626,013 of which approximately 20.1% were held by Founders, Directors and Management. Additional information about the Company is available on BULGOLD’s website (www.BULGOLD.com) and on SEDAR (www.sedarplus.ca).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Information

This press release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”). All statements other than statements of historical fact may be forward‐looking statements or information. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this press release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this press release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements and information contained in this press release are expressly qualified by this cautionary statement.

For further information, please contact:

BULGOLD Inc.
Sean Hasson, President and Chief Executive Officer
Telephone: +359 887 560 545
Email: sean.hasson@BULGOLD.com
Website: www.BULGOLD.com

LOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) — Stargaze Entertainment Group Inc. (OTC: STGZ), an entertainment and technology company focused on discovering and elevating emerging talent through its proprietary digital platforms, today announced updated details for its exclusive online dance competition hosted by world-renowned dance icon Abby Lee Miller on the Stargaze Stage™ platform.

The Abby Lee Miller Dance Competition has extended its submission deadline through October 31, 2026, giving dancers additional time to showcase their talent with free entry, perform for Abby Lee Miller, and receive direct evaluation from her through a fully digital format. Dancers can enter by submitting their best performance through the Challenges section of the Stargaze Stage™ app.

Submitted performances may be up to two minutes and 20 seconds in length and should showcase each dancer’s personality, technique, performance quality, and star power.

Abby Lee and her team will personally review the submissions and select the Top 50 dancers based on talent, performance ability, stage presence, and potential. Those selected will be notified directly through the Stargaze Stage app and invited to submit an additional performance video of up to one minute.

Abby Lee will then review the Top 50 submissions, with the five highest-scoring dancers advancing to the live Grand Finale. Stargaze Pro members who reach the Top 50 will also receive personalized feedback from Abby Lee based on their performances.

The Top 5 finalists will come together for the Abby Lee Miller Dance Challenge Grand Finale, with the date to be announced, streaming live exclusively on Stargaze Stage™. During the live event, Abby Lee will evaluate the finalists and ultimately crown the winner of the Abby Lee Miller Dance Challenge live on the app.

The Grand Prize winner will receive an exclusive one-on-one virtual mentoring session with Abby Lee, one year of complimentary access to Abby Lee’s Zoom classes, a complimentary one-year Stargaze Pro Membership, and an Abby Lee Dance Company swag bag.

The competition will be promoted across Abby Lee’s official social media channels as well as Stargaze’s digital network, offering participating artists meaningful exposure to both fans and industry professionals.

“This collaboration highlights the power of Stargaze Stage as a next-generation digital venue for talent discovery,” said a spokesperson for Stargaze Entertainment Group. “By combining industry legends with accessible technology, we are removing traditional barriers and creating real opportunities for artists worldwide.”

Stargaze Stage is designed to give performers direct access to influential decision-makers through live and on-demand digital events, redefining how emerging talent is discovered, showcased, and monetized.

HOW TO ENTER

Dancers must download Stargaze Stage™, create and complete their performer profile, and enter through the Challenges section of the app. Entries must include a dance performance video submitted no later than October 31, 2026.

One upload. One opportunity. Your moment to stand out starts here.

About Stargaze Entertainment Group Inc.

Stargaze Entertainment Group Inc. (OTC: STGZ) is an entertainment technology company focused on talent discovery, content creation, and audience engagement. Through its Stargaze Stage™ platform, the company provides artists with innovative tools to showcase their work, connect with industry professionals, and reach global audiences.

Stargaze Stage™

The Stage Is Yours.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update forward-looking statements except as required by law.

For more information, visit www.stargazestage.com.

CONTACT: Investor and Media Contact:
Stargaze Entertainment Group.
312.867.1800
Team@stgz.tv

Submissions Now Open for the Morgan Dudley Broadway Challenge, Presented in Partnership with Eris Talent Agency

CHICAGO, Oct. 02, 2026 (GLOBE NEWSWIRE) — Stargaze Entertainment Group, Inc. (OTC: STGZ) (“Stargaze” or the “Company”), the entertainment technology company behind Stargaze Stage™, today announced the launch of the Morgan Dudley Broadway Challenge, a search for Broadway’s next breakout performer.

The Morgan Dudley Broadway Challenge has extended its submission deadline through October 31, 2026, giving aspiring performers additional time to showcase their talent and audition by uploading their Broadway-inspired performances directly through the Challenges section of the Stargaze Stage™ app.

Every Broadway career begins with a single opportunity.

For Morgan Dudley, that opportunity came years ago when she uploaded an audition to Scenebot Stage, the original platform that has since evolved into Stargaze Stage™. That opportunity introduced Morgan to the entertainment industry, ultimately leading to professional representation and starring roles in Broadway’s Jagged Little Pill, Disney’s Descendants: The Rise of Red, and her current role in the Tony Award-winning musical Hadestown.

Today, Morgan returns to the platform that helped launch her own journey—not as a contestant, but to help discover the next performer whose career could change with one audition.

“I know what it feels like to wonder if anyone will ever see your talent,” said Morgan Dudley. “One opportunity changed everything for me. Coming back to Stargaze Stage to help someone else take that same first step is incredibly meaningful. I can’t wait to discover the next generation of Broadway performers and celebrate their journey.”

ONE AUDITION. ONE OPPORTUNITY.

One exceptional performer will be offered theatrical representation by Eris Talent Agency, subject to the agency’s standard representation agreement.

If the selected winner resides outside the United States or is otherwise unable to be represented in the U.S., the winner will instead receive a private mentorship session with a leading talent agent or casting director to help accelerate their professional career within their home market.

INTRODUCING THE INAUGURAL MORGAN DUDLEY & FRIENDS BROADWAY SHOWCASE

Following the close of submissions on October 31, selected finalists will be featured during the inaugural Morgan Dudley & Friends Broadway Showcase, an exclusive live entertainment event streaming on Stargaze Stage™ later this September.

Hosted by Morgan Dudley, the showcase will feature live performances from Morgan and special guests, conversations about the opportunities and mentors that helped shape their own careers, highlights from the competition’s top finalists, demonstrations of the newest Stargaze Stage features, and culminate with the live announcement of the Morgan Dudley Broadway Challenge winner.

The winning performer will then join Morgan live on the show as the newest chapter in the Stargaze Stage story begins.

Designed as both a celebration of emerging talent and a showcase of Stargaze Stage’s unique live-performance ecosystem, the event marks the beginning of a new generation of interactive talent discovery.

THE BEGINNING OF THE STARGAZE STAGE CREATOR SERIES

The Morgan Dudley Broadway Challenge is the inaugural event in the Stargaze Stage Creator Series—an ongoing lineup of celebrity-led career opportunities connecting aspiring artists with accomplished entertainment professionals.

Additional celebrity partnerships, creator competitions, mentors, advisors, and career opportunities spanning acting, singing, Broadway, dance, comedy, music, and other creative disciplines will be announced throughout the coming months.

Rather than functioning solely as another social platform, Stargaze Stage is building an always-on destination where creators can perform live, compete in professionally produced challenges, receive mentorship from respected industry professionals, monetize their audiences, and create genuine pathways toward professional careers.

BUILDING THE FUTURE OF TALENT DISCOVERY

“Talent has never been limited by geography or circumstance—only by opportunity,” said Steve Mandell, Chief Executive Officer of Stargaze Entertainment Group. “For nearly a decade, Scenebot Stage helped extraordinary performers connect with real opportunities throughout the entertainment industry. Stargaze Stage is the natural evolution of that mission. We’re not simply building another creator platform—we’re building a place where extraordinary talent can finally be seen.”

Mandell continued, “Morgan’s story perfectly represents everything Stargaze Stage stands for. She trusted the process, worked tirelessly, and built an incredible career. Today she’s returning to help open that same door for someone else, and we couldn’t imagine a better way to introduce this next chapter for Stargaze Stage.”

A PROVEN FOUNDATION. A BIGGER VISION.

Built upon the legacy of Scenebot Stage, which helped facilitate nearly 1,000 career opportunities across Broadway, television, film, music, and digital media, Stargaze Stage™ represents the next evolution of talent discovery.

The platform combines live performance, short-form video, professionally produced creator competitions, mentorship, audience engagement, and meaningful career opportunities into one integrated global entertainment ecosystem.

By giving creators a stage to perform, audiences a place to discover tomorrow’s stars, and industry professionals direct access to emerging talent, Stargaze Stage is redefining how careers begin in the digital age.

YOUR BROADWAY AUDITION STARTS TODAY.

Submissions for the Morgan Dudley Broadway Challenge are now open exclusively through Stargaze Stage™ and will remain open through October 31.

Download Stargaze Stage™ on the Apple App Store or Google Play and submit your audition for an opportunity to perform during the Morgan Dudley & Friends Broadway Showcase and take the first step toward a professional career.

About Stargaze Entertainment Group, Inc. (OTC: STGZ)

Stargaze Entertainment Group, Inc. is an entertainment technology company developing Stargaze Stage™, a next-generation talent discovery platform that combines live performance, short-form video, creator competitions, professional mentorship, and audience engagement into one global entertainment destination.

Built on the proven legacy of Scenebot Stage, which helped facilitate nearly 1,000 career opportunities across Broadway, television, film, music, and digital media, Stargaze Stage empowers creators to showcase their talent, build an audience, earn recognition, and pursue meaningful opportunities throughout the entertainment industry.

Stargaze Stage™

The Stage Is Yours.

For more information, visit www.stargazestage.com.

CONTACT: Investor and Media Contact:
Stargaze Entertainment Group.
312.867.1800
Team@stgz.tv

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Tate & Lyle plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	01/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	29 1/6p ordinary
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:
(2)   Cash-settled derivatives:	15,481,929	3.47%
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	15,481,929	3.47%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
29 1/6p ordinary	CFD	Increasing a long position	1,401,300	GBP 5.5850

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	02/10/2026
Contact name:	Alex McMillan
Telephone number:	646 282 5805

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.      KEY INFORMATION

(a)   Full name of discloser	Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree	DCC plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
(e)   Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure	01/10/2026
(f)   In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”	No

2.      INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)

Class of relevant security (Note 3)	€0.25 Ordinary Shares (ISIN – IE0002424939)
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled
(2)   Cash-settled derivatives	856,074	1.00%
(3)   Stock-settled derivatives (including options) and agreements to purchase/ sell
Total	856,074	1.00%

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.      DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)      Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit (Note 5)

(b)      Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing	Number of reference securities (Note 6)	Price per unit
€0.25 Ordinary Shares	CFD	Reducing a long position	37,680	GBP 64.4000

(c)      Stock-settled derivative transactions (including options)

(i)      Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates (Note 6)

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)      Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 3)

Class of relevant security

Nature of dealing e.g. subscription, conversion, exercise

Details

Price per unit (if applicable) (Note 5)

4.      OTHER INFORMATION

(a)      Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b)      Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

(c)        Attachments

Is a Supplemental Form 8 attached?

NO

Date of disclosure	02/10/2026
Contact name	Alex McMillan
Telephone number	646 282 5805

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

NOTES ON FORM 8.3

1.      See the definition of “connected fund manager” in Rule 2.2 of Part A of the Rules.

2.      See the definition of “interest in a relevant security” in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.

3.      See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules.

4.      See the definition of “dealing” in Rule 2.1 of Part A of the Rules.

5.      If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

6.      See Rule 2.5(d) of Part A of the Rules.

7.      If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Bid procedure, 2026-10-09
Bonds	SWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01 SWEDEN I/L BOND: 3104, SE0000556599, 2028-12-01
Bid date	2026-10-09
Bid times	09.00-10.00 (CET/CEST) on the Bid date
Offered volume (corresponding nominal amount)	3113: 250 million SEK +/-250 million SEK 3104: 150 million SEK +250/-150 million SEK
Highest permitted bid volume (corresponding nominal amount)	3113: 250 million SEK per bid 3104: 150 million SEK per bid
Lowest permitted bid volume (corresponding nominal amount)	SEK 10 million per bid
Expected allocation time	Not later than 10.15 (CET/CEST) on the Bid date
Delivery and payment date	2026-10-13
Settlement amount	To be paid to the Riksbank’s account in Euroclear Sweden AB’s securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK

Stockholm, 2026-10-02

This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

Title: Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) in Patients with Refractory Systemic Sclerosis
Session Type: Poster Presentation
Abstract Number: 0225
Session Name: Poster Session A
Date and Time: Sunday, November 8, 2026, 10:30 a.m. ET

Zugo-cel is being evaluated in Phase 1 trials across autoimmune diseases, including rheumatologic, hematologic and neurologic indications.

A copy of the presentation will be available at www.crisprtx.com once the presentation concludes.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY^® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

CRISPR THERAPEUTICS^® standard character mark and design logo and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY^® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners. 

CRISPR Therapeutics Forward-Looking Statement
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials and expectations regarding data, safety and efficacy generally; (ii) data included in the above-described poster presentation and any associated abstract; and (iii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9, as well as other technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in CRISPR Therapeutics most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Investor Contact: 
+1-617-307-7503 
ir@crisprtx.com

Media Contact: 
 +1-617-315-4493 
media@crisprtx.com

A universal boost for today’s systems that delivers the speed tomorrow’s networks demand

Close up image of patented FORTITUDE™ multilayer chip technology. (Photo: Northrop Grumman)

BALTIMORE, Oct. 02, 2026 (GLOBE NEWSWIRE) — (PHOTO RELEASE): Designed to solve one of the hardest problems in modern electronics — moving massive amounts of information quickly, cleanly and reliably — Northrop Grumman’s FORTITUDE™ processes vast portions of the electromagnetic spectrum on a single, grain-of-rice–sized gallium nitride chip. The future-ready technology delivers three times more power and 20 times better signal quality, helping satellites, radar, GPS, electronic warfare and future 6G systems stay connected with clearer, more reliable performance.

Previously known as the Super Lattice Castellated Field Effect Transistor, FORTITUDE™ builds on the company’s focused research and development and substantial investment in microelectronics to replace dozens of components, cutting weight, and slashing power consumption while delivering greater value for the end system. Built in the U.S. for both commercial and defense markets, FORTITUDE™ simplifies system architectures and opens new opportunities for faster, more dependable communications across next generation platforms.

Learn more about Northrop Grumman’s FORTITUDE™ here.

Contact:  Leslie Zychowski
410-218-1395 
leslie.zychowski@ngc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/083cc2e0-2715-47d9-8c66-9c3490a61eb5

DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, taking place in Denver, CO, October 21 – 25, 2026.

Presentation Details:

Title: Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (SAVE) with a Historical Cohort

Authors: Nathan L. Kleinman, Stuart Goldstein, Rajit K. Basu, Theresa A. Mottes, David J. Askenazi, Stephen Gorga, Shina Menon, Matt S. Zinter, Keri A. Drake, David A. Zolezzi, Robert S. Gillespie, Sai Prasad N. Iyer, Emily Scribe, Kevin K. Chung

Abstract / Poster Number: TH-PO1291

Date & Time: October 22, 2026, from 10:00 a.m. to 12:00 p.m. MT

Location: Exhibit Hall A, Colorado Convention Center

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Contact:  
IR@SEASTARMED.COM

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.